The trial will evaluate talabostat plus pemetrexed, and compare the combination with pemetrexed plus placebo.
The newly initiated phase III trial is being conducted as part of a phase III clinical program in non-small cell lung cancer (NSCLC) consisting of two randomized, double blind placebo controlled trials in up to 800 patients at approximately 100 sites in North America.
“Initiating patient enrollment in our second phase III trial is an important milestone for talabostat’s development and the company overall,” said Don Kiepert, president and CEO of Point Therapeutics. “We are excited about studying talabostat in our two phase III trials in metastatic non-small cell lung cancer patients who have failed at least one prior course of chemotherapy,” concluded Kiepert.